MedTrace Logo

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

NCT05645380 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2026-04-28

No results posted yet for this study

Summary

This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.

Conditions

Interventions

DRUG

Carboplatin

AUC=6, IV

DRUG

Docetaxel

75 mg/m2, IV

DRUG

Doxorubicin

60 mg/m2, IV

DRUG

Cyclophosphamide

600 mg/m2, IV

DRUG

Pembrolizumab

200 mg, IV

Sponsors & Collaborators

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Priyanka Sharma, MD · University of Kansas Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-05
Primary Completion
2026-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05645380 on ClinicalTrials.gov